TITLE

The Global Epidemic of Obesity: Why Global Approaches Won't Work

AUTHOR(S)
Miller, Wayne C.
PUB. DATE
November 2001
SOURCE
Healthy Weight Journal;Nov/Dec2001, Vol. 15 Issue 6, p81
SOURCE TYPE
Periodical
DOC. TYPE
Editorial
ABSTRACT
Editorial. Explores the global epidemic of obesity. Efforts to prevent overweight and obesity; Assumptions underlying obesity treatment paradigms; Efficiency of obesity treatment programs.
ACCESSION #
5459140

 

Related Articles

  • New anti obesity drug for 2007. Wynyard, Ruth // New Zealand Doctor;6/14/2006, p6 

    Reports that the anti-obesity drug rimonabant will be available in the Australian market by the end of 2007. Possible availability of the drug in the U.S. in 2008; View of nutritionist and professor Jim Mann on the drug.

  • Let's Treat Obesity Seriously. BRAY, GEORGE A. // American Family Physician;6/15/2010, Vol. 81 Issue 12, p1406 

    The author discusses the need for physicians to treat obesity seriously. He mentions that 66 percent of U.S. adults are overweight and 33 percent are obese based on a study. He says that obese patients often have different kinds of health problems aside from excess weight like depression,...

  • appetite auppresant (Major drug group).  // Royal Society of Medicine: Medicines;2002, p84 

    The article presents information on appetite auppresants. These drugs are used to treat obesity. The first of the drugs acting on the brain, and a number of such drugs that have been used are related and have actions similar to the stimulant amfetamine. The second type of appetite suppressants...

  • Obesity spending rises seven-fold. Tanday, Sanjay // GP: General Practitioner;4/10/2009, p4 

    The article focuses on the seven-fold increase of obesity spending among the Primary Care Trusts (PCTs) in Great Britain over the past three years. One survey shows that half of all PCTs increased their obesity budget and treated more patients than they had done in the previous two years. They...

  • Editorial [Hot Topic:Botanical Treatments for Diabetes and Obesity (Guest Editor: Jianping Ye)]. Jianping Ye // Endocrine, Metabolic & Immune Disorders - Drug Targets;Jun2008, Vol. 8 Issue 2, p77 

    Type 2 diabetes, obesity, metabolic syndrome, and their cardiovascular complications represent a major public health problem around the world. Strategies for effective prevention and treatment for these devastating diseases are of great interest to the general public, government organization,...

  • Obesity Treatment and Trends, Today and Tomorrow. Harris, Michael // BioWorld International;5/26/2010, Vol. 15 Issue 21, Special section p1 

    The article discusses various issues concerning obesity. It reveals that obesity is globally increasing but the drug and medical technology markets has become reliant on developed products for major illnesses. Surgery, according to the author, is the treatment of choice for obesity. They...

  • Capítulo1: Metabolismo energético. Krupa Das, Sai; B. Roberts, Susan // Conocimientos Actuales sobre Nutrición;2003, p3 

    The energetic equilibrium is adjusted by particularly sensitive mechanisms which have been identified during the present investigations. The disorders in the energetic equilibrium emerge from the genetic and environmental causes and explain many of the current common health problems in the...

  • A medicinal plants survey for treatment of obesity. Kumar, D. Sathis; Banji, David; Harani, A. // Journal of Pharmacy Research;Mar2011, Vol. 4 Issue 3, p597 

    The present day problem right from young people including all the age groups is obesity. It is not just fatness but is the indication of overweight. The plants with several chemical constituents with in themselves act as the source for the treatment of the obesity with their valuable...

  • Novel obesity drugs, oncology biosimilars to impact markets.  // PharmacoEconomics & Outcomes News;10/3/2009, Issue 588, p11 

    The article discusses the statement by Decision Resources that by 2018, obesity drug market is expected to grow more than six times and biosimilars are expected to erode sales of three branded oncology drugs. According to this report, biosimilars of the oncology drugs rituximab, cetuximab and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics